Junshi, Coherus build a case for U.S. PD-1 inhibitor approval

Junshi and its U.S. partner Coherus will present positive Phase III data at ASCO for toripalimab that support a rolling BLA submission, building Chinese competition in the U.S. PD-1 market that could eventually challenge the high prices of the drug class.

In a late-breaking abstract released in advance of the American Society of Clinical Oncology (ASCO) meeting, the partners reported that toripalimab met the primary PFS endpoint in first-line recurrent or metastatic nasopharyngeal carcinoma...